FY2025 · period end Dec '25 · from the 10-K filed Feb 13, 2026
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B |
| Gross Profit | $24.71B | $20.57B | $19.74B | $19.92B | $19.52B |
| Operating Income | $9.08B | $7.26B | $7.90B | $9.57B | $7.64B |
| Net Income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| EPS (Diluted) | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $90.59B | $91.84B | $97.15B | $65.12B | $61.16B |
| Total Liabilities | — | — | — | — | — |
| Stockholders' Equity | $8.66B | $5.88B | $6.23B | $3.66B | $6.70B |
| Cash & Equivalents | $9.13B | $11.97B | $10.94B | $7.63B | $7.99B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $9.96B | $11.49B | $8.47B | $9.72B | $9.26B |
| Capital Expenditures | $1.86B | $1.10B | $1.11B | $0.94B | $0.88B |
| Free Cash Flow | $8.10B | $10.39B | $7.36B | $8.79B | $8.38B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 67.2% | 61.5% | 70.0% | 75.7% | 75.2% |
| Operating Margin | 0.2% | 0.2% | 0.3% | 0.4% | 0.3% |
| Net Margin | 0.2% | 0.1% | 0.2% | 0.2% | 0.2% |
| Return on Equity | 106.1% | 67.6% | 135.8% | 126.5% | 73.2% |
| Return on Assets | 8.5% | 4.3% | 8.3% | 10.4% | 9.5% |
| Debt / Equity | 6.31× | 10.23× | 10.37× | 10.64× | 4.97× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or unlimited history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0000318154-26-000126 | Jun 30, 2026 | Aug 5, 2026 | Aug 4, 2026 22:29 UTC | EDGAR |
| 8-K | 0000318154-26-000124 | Aug 4, 2026 | Aug 4, 2026 | Aug 4, 2026 20:03 UTC | EDGAR |
| 8-K | 0000318154-26-000119 | Jul 29, 2026 | Jul 31, 2026 | Jul 31, 2026 20:03 UTC | EDGAR |
| 8-K | 0001193125-26-232786 | May 19, 2026 | May 20, 2026 | May 20, 2026 20:59 UTC | EDGAR |
| 8-K | 0000318154-26-000097 | May 19, 2026 | May 19, 2026 | May 19, 2026 20:08 UTC | EDGAR |
| 10-Q | 0000318154-26-000057 | Mar 31, 2026 | May 1, 2026 | Apr 30, 2026 23:04 UTC | EDGAR |
| 8-K | 0000318154-26-000054 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 20:03 UTC | EDGAR |
| 8-K | 0000318154-26-000048 | Apr 22, 2026 | Apr 22, 2026 | Apr 22, 2026 20:03 UTC | EDGAR |
Direct links to SEC EDGAR. AMGN has additional filings available on the SEC site.
6 numbers AMGEN INC later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·Q2 2015
Major restatementwas$4.1B
Revised up in a 10-Q. Any P/OCF built on the original was 13.1% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2015
Major restatementwas$1.3B
Revised up in a 10-Q. Any P/OCF built on the original was 10.3% too high.
Net Cash Provided by (Used in) Operating Activities·Q3 2015
Notable restatementwas$7B
Revised up in a 10-Q. Any P/OCF built on the original was 8.4% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2015
Notable restatementwas$9.1B
Revised up in a 10-K. Any P/OCF built on the original was 6.7% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2014
Notable restatementwas$8.6B
Revised up in a 10-K. Any P/OCF built on the original was 4.4% too high.
Net Cash Provided by (Used in) Operating Activities·FY 2013
Notable restatementwas$6.3B
Revised up in a 8-K. Any P/OCF built on the original was 3.6% too high.
AMGN is not the only one.
See every restatement we've found across the market — or get an alert the next time AMGN revises a number.
Restatements are detected by comparing every vintage of a fact across all of AMGEN INC's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows AMGN's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling AMGEN INC — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on AMGN yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows, every figure pinned to its SEC filing. Be the first: run equity_research_brief on AMGN and publish the result to your public profile.
Ask about AMGEN INC
Continue in Workspace — cited answers on AMGN, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate with zero survivorship bias.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs